CTEA.L Share News (CTEA)

(Sharecast News) - Digital media and technology company Catenae Innovation announced on Friday that its occupational health and wellness partner Newcastle Premier Health (NPH) has completed the proof of concept pilot trial of its 'Cov-ID' app.
The AIM-traded firm said NPH provided its clinical expertise to the Cov-ID project, and had been piloting the app since 29 May.

It described the Cov-ID app as a Covid-19 'status verification passport', designed to support the efforts of businesses and organisations in getting back to work, while safeguarding employees from the spread of the coronavirus by allowing the user to share and prove their Covid-19 status in a "secure, immutable and GDPR-compliant" way.

The objective of the pilot trial was to undertake a proof-of-concept of the app, to determine that user management, certification management and user validation achieved functionality targets, which included importing, creating and archiving certificate and user data, and viewing data via secure means through both one-way and two-way validation processes.

Both the one-way and two-way validation processes worked across Android and iOS platforms, the board said.

The app allows a user, or 'certificate holder' to expose their Covid-19 antibody testing status to a third-party 'gatekeeper' via a single-use QR code displayed on their device.

In one-way validation, the QR code is readable by any device equipped with QR scanner functionality or app.

In two-way validation mode, both the gatekeeper and the certificate holder use the app, allowing the identity of the gatekeeper to be validated, and restricting the display of the certificate holder's status solely to the gatekeeper.

Additionally, the event is logged and recorded to a blockchain repository.

Catenae asi the Cov-ID project was a joint initiative by a consortium of companies, led by the Z/Yen Group.

Although the proof-of-concept stage of the app was positive, the board said there was no guarantee that it would be commercialised, nor that in the event that it was commercialised, that material revenues would be generated by the company.

"The scope of the pilot trial was ambitiously expanded midway through to include the one-way validation usage on top of the initial two-way validation usage objective," noted interim chief executive officer Guy Meyer.

"Some minor graphic design refinements, based on NPH's feedback, will be completed within the next three weeks and then the Cov-ID app will be ready to be rolled out commercially across the UK and beyond to the benefit of businesses and organisations alike as the nations of the world begin to return to a semblance of normality."

At 1504 BST, shares in Catenae Innovation were down 12% at 3.08p.